Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo

AIM: The goal of this study was to determine if a single AAV vector, encoding Cas9 and guide RNAs specific for the HPV16 E6 and E7 genes, could inhibit the growth of an HPV16-induced tumor in vivo. MATERIALS & METHODS: We grew HPV16(+), patient-derived anal cancer explants in immunodeficient mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, David S, Kornepati, Anand VR, Glover, Wayne, Kennedy, Edward M, Cullen, Bryan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136077/
https://www.ncbi.nlm.nih.gov/pubmed/30245733
http://dx.doi.org/10.2217/fvl-2018-0010
Descripción
Sumario:AIM: The goal of this study was to determine if a single AAV vector, encoding Cas9 and guide RNAs specific for the HPV16 E6 and E7 genes, could inhibit the growth of an HPV16-induced tumor in vivo. MATERIALS & METHODS: We grew HPV16(+), patient-derived anal cancer explants in immunodeficient mice and then challenged these by injection of AAV-based vectors encoding Cas9 and control or HPV16-specific guide RNAs. RESULTS & CONCLUSION: We observed a significant and selective reduction in tumor growth when the HPV16 E6 and E7 genes were targeted using Cas9. These studies provide proof of principle for the hypothesis that CRISPR/Cas has the potential to be used to selectively treat HPV-induced tumors in humans.

Ejemplares similares